Posts

Showing posts with the label Research and Development

Subscribe Now!

DMCC - Dharamsi Morarji Chemical Company - Company Overview

Image
Dharamsi Morarji Chemical Company - Company Overview The Dharamsi Morarji Chemical Company Limited (DMCC), established in 1919, was the first producer of Sulphuric Acid and Phosphate fertilizers in India. Over the years, the brand of the Company (“Ship”) came to be recognized as the quality standard for Single Superphosphate (SSP). Until recently, DMCC was known primarily as a fertilizer producer, with over 75% of revenue from SSP. As a strategy, DMCC structured itself to Speciality Chemicals. With focused Research and Development efforts, processes for downstream sulfur-based chemicals were commercialized. Diversified Product & Customer Base The company has 34 unique products across bulk and specialty chemicals. The company has a wide product basket that helps us in penetrating new geographies and acquiring new customers. The chemicals manufactured and applied in a wide range of industries across 25 countries. Impact on Bulk Chemicals Companies  bulk chemicals had an unfavorable m

Indoco Remedies - Growth Back on Track

Image
 Indoco Remedies Ltd. - Company Overview Twitter Handle: @shuchi_nahar 1. Company Profile The company was established in 1947. Indoco is a small-sized pharma company engaged in manufacture, marketing and distribution of pharmaceutical products and services in the domestic & international markets. Through its nine marketing divisions viz. Indoco, Spade, Warren NexGen, Warren ACE, Warren Excel and Vision, Indoco Focus, Indoco CND, Spera and Institution the company serves a range of doctor specialties. Indoco has signed supply agreements with companies like Watson, Aspen and DSM to supply formulations to advanced and emerging markets. Figure:1 Graph Showing Revenue Trend & Revenue Breakup 2. India formulations growth core to overall growth Domestic formulations (~63% of FY20 revenues) grew at 6.5% CAGR in FY16-20. The subdued growth can be attributed to high concentration of acute therapies and one of the lowest MR productivities. With a market share of ~0.7% and overall rank o